5-Hydroxymethyl-2′-deoxyuridine, but not temozolomide, enhances the selective synthetic lethality in BRCA1 and BRCA2-deficient cells caused by PARP inhibition

被引：1
|
作者：
Clement, Jean [1 ]
Nakamura, Jun [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-4486
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4486
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Restoration of Replication Fork Stability in BRCA1-and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
    Taglialatela, Angelo
    Alvarez, Silvia
    Leuzzi, Giuseppe
    Sannino, Vincenzo
    Ranjha, Lepakshi
    Huang, Jen-Wei
    Madubata, Chioma
    Anand, Roopesh
    Levy, Brynn
    Rabadan, Raul
    Cejka, Petr
    Costanzo, Vincenzo
    Ciccia, Alberto
    MOLECULAR CELL, 2017, 68 (02) : 414 - +
  • [32] Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
    Ragupathi, Ashwin
    Singh, Manrose
    Perez, Alexis M.
    Zhang, Dong
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [33] Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance
    Tacconi, Eliana M. C.
    Badie, Sophie
    De Gregoriis, Giuliana
    Reislander, Timo
    Lai, Xianning
    Porru, Manuela
    Folio, Cecilia
    Moore, John
    Kopp, Arnaud
    Torres, Julia Baguna
    Sneddon, Deborah
    Green, Marcus
    Dedic, Simon
    Lee, Jonathan W.
    Batra, Ankita Sati
    Rueda, Oscar M.
    Bruna, Alejandra
    Leonetti, Carlo
    Caldas, Carlos
    Cornelissen, Bart
    Brino, Laurent
    Ryan, Anderson
    Biroccio, Annamaria
    Tarsounas, Madalena
    EMBO MOLECULAR MEDICINE, 2019, 11 (07)
  • [34] BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-Ribose) polymerase
    McCabe, N
    Lord, CJ
    Tutt, ANJ
    Martin, NMB
    Smith, GCM
    Ashworth, A
    CANCER BIOLOGY & THERAPY, 2005, 4 (09) : 934 - 936
  • [35] Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52-ssDNA association
    Li, Jian
    Yang, Qianye
    Zhang, Yang
    Huang, Kejia
    Sun, Rong
    Zhao, Qi
    RSC ADVANCES, 2018, 8 (34) : 18859 - 18869
  • [36] A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells
    Dagg, Rebecca A.
    Zonderland, Gijs
    Lombardi, Emilia Puig
    Rossetti, Giacomo G.
    Groelly, Florian J.
    Barroso, Sonia
    Tacconi, Eliana M. C.
    Wright, Benjamin
    Lockstone, Helen
    Aguilera, Andres
    Halazonetis, Thanos D.
    Tarsounas, Madalena
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [37] A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells
    Rebecca A. Dagg
    Gijs Zonderland
    Emilia Puig Lombardi
    Giacomo G. Rossetti
    Florian J. Groelly
    Sonia Barroso
    Eliana M. C. Tacconi
    Benjamin Wright
    Helen Lockstone
    Andrés Aguilera
    Thanos D. Halazonetis
    Madalena Tarsounas
    Nature Communications, 12
  • [38] PARP Inhibition: Genomics-Informed Care for Patients With Malignancies Driven by BRCA1/BRCA2 Pathogenic Variants
    Hines-Mitchell, Carissa
    Mahon, Suzanne M.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2023, 27 (02) : 181 - 189
  • [39] The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells
    Simoneau, Antoine
    Xiong, Rosalinda
    Zou, Lee
    GENES & DEVELOPMENT, 2021, 35 (17-18) : 1271 - 1289
  • [40] Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
    Aziz, Diar
    Portman, Neil
    Fernandez, Kristine J.
    Lee, Christine
    Alexandrou, Sarah
    Llop-Guevara, Alba
    Phan, Zoe
    Yong, Aliza
    Wilkinson, Ashleigh
    Sergio, C. Marcelo
    Ferraro, Danielle
    Etemadmoghadam, Dariush
    Bowtell, David D.
    Serra, Violeta
    Waring, Paul
    Lim, Elgene
    Caldon, C. Elizabeth
    NPJ BREAST CANCER, 2021, 7 (01)
12345